LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Search

Celldex Therapeutics Inc

Gesloten

SectorGezondheidszorg

24.44 -0.77

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

23.2

Max

24.64

Belangrijke statistieken

By Trading Economics

Inkomsten

-10M

-67M

Winstmarge

-7,753.425

Werknemers

186

EBITDA

-9.8M

-73M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+77.35% upside

Dividenden

By Dow Jones

Volgende Winsten

25 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

143M

1.6B

Vorige openingsprijs

25.21

Vorige sluitingsprijs

24.44

Nieuwssentiment

By Acuity

50%

50%

149 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 feb 2026, 23:47 UTC

Populaire aandelen

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11 feb 2026, 22:59 UTC

Winsten
Acquisities, Fusies, Overnames

Grab Holdings to Buy U.S.-Based Stash Financial

11 feb 2026, 23:54 UTC

Winsten

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11 feb 2026, 23:50 UTC

Marktinformatie

Global Equities Roundup: Market Talk

11 feb 2026, 23:50 UTC

Marktinformatie

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11 feb 2026, 23:49 UTC

Winsten

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11 feb 2026, 23:45 UTC

Winsten

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11 feb 2026, 23:42 UTC

Winsten

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11 feb 2026, 23:41 UTC

Winsten

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11 feb 2026, 23:40 UTC

Winsten

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11 feb 2026, 23:35 UTC

Marktinformatie

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11 feb 2026, 23:18 UTC

Marktinformatie

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11 feb 2026, 23:14 UTC

Marktinformatie

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11 feb 2026, 22:59 UTC

Winsten

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11 feb 2026, 22:59 UTC

Winsten

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11 feb 2026, 22:59 UTC

Winsten

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11 feb 2026, 22:58 UTC

Winsten

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11 feb 2026, 22:57 UTC

Winsten

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11 feb 2026, 22:54 UTC

Winsten

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11 feb 2026, 22:53 UTC

Winsten

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11 feb 2026, 22:47 UTC

Winsten

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 feb 2026, 22:47 UTC

Winsten

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 feb 2026, 22:23 UTC

Winsten

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11 feb 2026, 22:22 UTC

Winsten

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11 feb 2026, 22:22 UTC

Winsten

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11 feb 2026, 22:19 UTC

Winsten

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11 feb 2026, 22:18 UTC

Winsten

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11 feb 2026, 22:18 UTC

Winsten

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11 feb 2026, 22:18 UTC

Winsten

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11 feb 2026, 22:16 UTC

Winsten

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

77.35% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 44 USD  77.35%

Hoogste 62 USD

Laagste 24 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

4 ratings

3

Buy

0

Hold

1

Sell

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

149 / 352 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat